News

Medical Dialogues4h
Itepekimab met primary endpoint in one of two COPD phase 3 studies: Sanofi, Regeneron
Paris: Sanofi has announced that the AERIFY-1 phase 3 study evaluating itepekimab in former smokers with inadequately ...
European Medical Journal22h
Navigating Treatment Switch in Late-Onset Pompe Disease (LOPD)
This symposium, ‘A case-based approach to navigating treatment switch in late-onset Pompe Disease (LOPD)’, was held at the ...